There are currently more than a dozen DMTs approved for the treatment of MS, such as subcutaneous injection of Interferon-β (IFN-β), Fingolimod, Teriflunomide, Ocrelizumab, Natalizumab, etc. Here, IFNB1 is linked to myeloid sarcoma.